Articles related to ALZHEIMER'S/DEMENTIA

In a propensity-matched analysis of more than 66,000 adults with hypertension, blood-brain barrier (BBB)-crossing antihypertensives were associated with a 16% lower dementia risk than BBB-non-crossing agents. The observational design prevents causal conclusions but adds to growing interest in whether some antihypertensives may influence cognitive outcomes beyond blood pressure control.

A 10-year retrospective cohort study associated glaucoma with higher risks of Alzheimer disease, vascular dementia, and other neurodegenerative diagnoses, although administrative coding and surveillance bias limit causal interpretation.

Use of estrogen-only hormone therapy in women over age 70 was associated with lower rates of dementia diagnoses and reduced Alzheimer-related pathology across large observational cohorts. The findings identify an association but do not establish a preventive effect against dementia.

Among adults with both sleep disturbances and mild cognitive impairment, self-reported vitamin D supplementation of at least 5,000 IU daily was associated with higher cognitive assessment scores in a small observational study, while lower doses showed no similar association.

A meta-analysis of seven studies found cannabinoid-based therapies were associated with lower agitation and neuropsychiatric symptom scores in patients with moderate to severe Alzheimer disease. Cognitive benefits were not consistently observed, and somnolence occurred more frequently with treatment.

Among more than 7,300 Swedish patients with Alzheimer’s disease and atrial fibrillation, NOAC use was associated with slower cognitive decline than warfarin or no anticoagulation. The observational findings did not establish causality but suggest potential differences in long-term cognitive outcomes.